Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects.
The authors wished to investigate some aspects of the cell-mediated immunity in hemodialyzed subjects undergoing a treatment with recombinant erythropoietin (rHuEPO). The study was carried out through the dosage of the serum levels of neopterin, a substance produced by the macrophages and usable as a marker of their state of activation. The results show a significant reduction of the serum levels of pteridine already at the second month of treatment with rHuEPO (61 +/- 9 vs. 95 +/- 12 nmol/l), thus proving a probable inhibitory action carried out by erythropoietin on certain cells of the immune system.
Buemi
M
M
Chair of Nephrology II, Messina University, Italy.
Allegra
A
A
Aloisi
C
C
Frisina
N
N
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D001708:Biopterins / Q000031:analogs & derivatives* / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D019798:Neopterin; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin; D001708:Biopterins; D019798:Neopterin